ASTX030

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Near Add Your Location

Center of Excellence

  • Accepting patients

Center of Excellence

Center of Excellence

New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

Vanderbilt-Ingram Cancer Center
Henry-Joyce Cancer Clinic
Nashville, TN
  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients
  • Accepting patients

Center of Excellence

496 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.